Advertisement
Screener

ENVERIC BIOSCIENCES, INC. (ENVB) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

1.4 / 5 stars · 20/74 Roast Me

ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $3.50 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2023-06-09

  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $3.50, a 112.12% increase year-over-year.
  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.65.
  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $81.00, a 4.14% decline from fiscal 2020.
  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $84.50, a 4146.23% increase from fiscal 2019.
  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2019 was $1.99.
  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2016 was $5.41.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed
2022-03-31$3.50
10-Q · filed 2022-05-13
2021-12-31$81.00
10-K/A · filed 2023-06-09
$1.69
10-K · filed 2022-03-31
2021-09-30$1.69
10-Q · filed 2021-11-15
2021-06-30$1.65
10-Q · filed 2021-08-13
2021-03-31$1.65
10-Q · filed 2021-05-17
2020-12-31$84.50
10-K/A · filed 2023-06-09
$1.94
10-K · filed 2021-04-01
2019-12-31$1.99
10-K · filed 2021-04-01
2016-12-31$5.41
10-K/A · filed 2017-04-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
Pulmatrix, Inc. (PULM)United States$0.006B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
EXICURE, INC. (XCUR)United States$0.008B-1.54